DEA moves on kratom substances as FDA greenlights new pancreatic drug

The Drug Enforcement Administration is taking new steps concerning substances associated with kratom, signaling a shift in how the agency handles the plant-derived compounds.

In a separate development, the Food and Drug Administration has granted approval for a new drug aimed at treating pancreatic conditions, marking a notable addition to the therapeutic landscape.

A report highlighted that Louisiana sheriffs have allocated millions of dollars from opioid settlement funds toward law‑enforcement equipment rather than addiction‑treatment programs, raising questions about the use of those resources.

Meanwhile, Robert F. Kennedy Jr. continued to downplay the seriousness of measles in recent social‑media posts, prompting criticism from public‑health officials and the Pennsylvania governor.

These items were featured together in a health‑focused newsletter that also covered other topics such as gender‑affirming care and mental health.